Treatment of large stage I-II lung tumors using stereotactic body radiotherapy (SBRT): Planning considerations and early toxicity

After SBRT using RapidArc in lung tumors >80 cm3, the contralateral lung V5 best predicts RP. Limiting contralateral lung V5 to <26% may reduce acute toxicity.